Abliva AB (publ) (ABLI.ST)
SEK 0.44
(0.23%)
SEK 0.44
(0.23%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 27.86 Million SEK | -36.85% |
| 2022 | 84.93 Million SEK | -31.12% |
| 2021 | 123.3 Million SEK | 104.18% |
| 2020 | 60.39 Million SEK | -21.45% |
| 2019 | 76.88 Million SEK | 5.94% |
| 2018 | 72.57 Million SEK | 1.8% |
| 2017 | 71.29 Million SEK | 41.23% |
| 2016 | 50.48 Million SEK | -22.66% |
| 2015 | 65.27 Million SEK | 24.55% |
| 2014 | 52.4 Million SEK | 89.32% |
| 2013 | 27.68 Million SEK | 67.77% |
| 2012 | 16.49 Million SEK | 6.96% |
| 2011 | 15.42 Million SEK | 98.39% |
| 2010 | 7.77 Million SEK | 29.57% |
| 2009 | 6 Million SEK | 139.3% |
| 2008 | 2.5 Million SEK | 104.34% |
| 2007 | 1.22 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 24.92 Million SEK | 34.55% |
| 2024 Q1 | 18.52 Million SEK | 11.22% |
| 2023 Q2 | 21.44 Million SEK | 32.22% |
| 2023 FY | 53.63 Million SEK | -36.85% |
| 2023 Q1 | 16.21 Million SEK | -17.01% |
| 2023 Q3 | 32.93 Million SEK | 53.63% |
| 2023 Q4 | 16.65 Million SEK | -49.44% |
| 2022 Q2 | 18.27 Million SEK | -15.21% |
| 2022 FY | 84.93 Million SEK | -31.12% |
| 2022 Q4 | 19.54 Million SEK | -23.58% |
| 2022 Q1 | 21.55 Million SEK | -41.1% |
| 2022 Q3 | 25.57 Million SEK | 39.93% |
| 2021 Q1 | 21.45 Million SEK | 60.29% |
| 2021 Q3 | 34.93 Million SEK | 15.19% |
| 2021 Q4 | 36.58 Million SEK | 4.72% |
| 2021 FY | 123.3 Million SEK | 104.18% |
| 2021 Q2 | 30.32 Million SEK | 41.38% |
| 2020 Q3 | 10.07 Million SEK | -50.64% |
| 2020 FY | 60.39 Million SEK | -21.45% |
| 2020 Q4 | 13.38 Million SEK | 32.9% |
| 2020 Q2 | 20.4 Million SEK | 23.37% |
| 2020 Q1 | 16.53 Million SEK | -38.64% |
| 2019 FY | 76.88 Million SEK | 5.94% |
| 2019 Q3 | 15.28 Million SEK | -26.65% |
| 2019 Q1 | 13.81 Million SEK | -28.62% |
| 2019 Q4 | 26.94 Million SEK | 76.29% |
| 2019 Q2 | 20.84 Million SEK | 50.91% |
| 2018 Q3 | 15.07 Million SEK | -40.09% |
| 2018 Q2 | 25.16 Million SEK | 93.66% |
| 2018 Q1 | 12.99 Million SEK | -13.95% |
| 2018 FY | 72.57 Million SEK | 1.8% |
| 2018 Q4 | 19.34 Million SEK | 28.33% |
| 2017 FY | 71.29 Million SEK | 41.23% |
| 2017 Q4 | 15.1 Million SEK | 18.04% |
| 2017 Q3 | 12.79 Million SEK | -42.24% |
| 2017 Q2 | 22.14 Million SEK | 4.16% |
| 2017 Q1 | 21.26 Million SEK | 414.22% |
| 2016 FY | 50.48 Million SEK | -22.66% |
| 2016 Q1 | 10.93 Million SEK | 151.28% |
| 2016 Q4 | -6.76 Million SEK | -119.79% |
| 2016 Q3 | 34.18 Million SEK | 182.11% |
| 2016 Q2 | 12.11 Million SEK | 10.8% |
| 2015 Q3 | 54.05 Million SEK | 203.24% |
| 2015 FY | 65.27 Million SEK | 24.55% |
| 2015 Q4 | -21.33 Million SEK | -139.46% |
| 2015 Q1 | 14.71 Million SEK | -15.66% |
| 2015 Q2 | 17.82 Million SEK | 21.11% |
| 2014 Q2 | 14.09 Million SEK | 42.96% |
| 2014 FY | 52.4 Million SEK | 89.32% |
| 2014 Q1 | 9.86 Million SEK | 6.18% |
| 2014 Q4 | 17.45 Million SEK | 58.71% |
| 2014 Q3 | 10.99 Million SEK | -21.98% |
| 2013 Q4 | 9.28 Million SEK | 39.2% |
| 2013 FY | 27.68 Million SEK | 67.77% |
| 2013 Q3 | 6.67 Million SEK | -2.77% |
| 2013 Q2 | 6.86 Million SEK | 41.09% |
| 2013 Q1 | 4.86 Million SEK | -9.15% |
| 2012 Q2 | 4.13 Million SEK | 44.61% |
| 2012 Q3 | 4.16 Million SEK | 0.73% |
| 2012 Q4 | 5.35 Million SEK | 28.68% |
| 2012 FY | 16.49 Million SEK | 6.96% |
| 2012 Q1 | 2.85 Million SEK | -11.39% |
| 2011 Q2 | 5.88 Million SEK | 98.87% |
| 2011 Q4 | 3.22 Million SEK | -4.01% |
| 2011 FY | 15.42 Million SEK | 98.39% |
| 2011 Q1 | 2.95 Million SEK | 24.81% |
| 2011 Q3 | 3.35 Million SEK | -42.94% |
| 2010 Q3 | 3.2 Million SEK | 150.77% |
| 2010 Q1 | 921.59 Thousand SEK | -56.19% |
| 2010 Q4 | 2.37 Million SEK | -26.02% |
| 2010 FY | 7.77 Million SEK | 29.57% |
| 2010 Q2 | 1.27 Million SEK | 38.67% |
| 2009 Q2 | 1.33 Million SEK | 29.03% |
| 2009 Q3 | 1.52 Million SEK | 14.7% |
| 2009 Q4 | 2.1 Million SEK | 37.54% |
| 2009 FY | 6 Million SEK | 139.3% |
| 2009 Q1 | 1.03 Million SEK | 0.0% |
| 2008 FY | 2.5 Million SEK | 104.34% |
| 2007 FY | 1.22 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Simris Alg AB (publ) | 38.64 Million SEK | 27.887% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 91.333% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 92.208% |
| Xintela AB (publ) | 57.31 Million SEK | 51.382% |
| Active Biotech AB (publ) | 44.8 Million SEK | 37.812% |
| Amniotics AB (publ) | 29.07 Million SEK | 4.148% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -90.173% |
| BioArctic AB (publ) | 89.62 Million SEK | 68.909% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.16% |
| Camurus AB (publ) | 1.05 Billion SEK | 97.37% |
| Cantargia AB (publ) | 290.01 Million SEK | 90.392% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -27.271% |
| CombiGene AB (publ) | 44.14 Million SEK | 36.875% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 80.512% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 1.625% |
| Genovis AB (publ.) | 88.19 Million SEK | 68.405% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 75.784% |
| Mendus AB (publ) | 129.13 Million SEK | 78.421% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -283.407% |
| Intervacc AB (publ) | 79.78 Million SEK | 65.074% |
| Kancera AB (publ) | 63.07 Million SEK | 55.822% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -404.91% |
| LIDDS AB (publ) | 27.75 Million SEK | -0.411% |
| Lipum AB (publ) | 37.3 Million SEK | 25.306% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -284.147% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 79.497% |
| NextCell Pharma AB | -576.01 Thousand SEK | 4937.688% |
| OncoZenge AB (publ) | 15.9 Million SEK | -75.203% |
| Saniona AB (publ) | 1.07 Million SEK | -2487.372% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 84.667% |
| Ziccum AB (publ) | 27.87 Million SEK | 0.043% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -69.904% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 90.926% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 34.636% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -57.586% |
| Corline Biomedical AB | 30.16 Million SEK | 7.631% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 51.981% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 66.495% |
| Aptahem AB (publ) | 10.01 Million SEK | -178.3% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 79.312% |
| Fluicell AB (publ) | 28.61 Million SEK | 2.624% |
| Biovica International AB (publ) | 133.72 Million SEK | 79.161% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -40.808% |
| AcouSort AB (publ) | 25.87 Million SEK | -7.691% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 85.599% |
| 2cureX AB (publ) | 36.51 Million SEK | 23.692% |
| I-Tech AB | 40.14 Million SEK | 30.592% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 96.758% |
| Cyxone AB (publ) | 28.21 Million SEK | 1.233% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 74.521% |
| Biosergen AB | 26.8 Million SEK | -3.943% |
| Nanologica AB (publ) | 69.88 Million SEK | 60.127% |
| SynAct Pharma AB | 224.49 Million SEK | 87.587% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 36.92% |
| BioInvent International AB (publ) | 441.4 Million SEK | 93.687% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -16.33% |
| Alzinova AB (publ) | 36.39 Million SEK | 23.437% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 90.383% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -254.698% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 74.876% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -89.565% |